Predicting progression to lymphoma in Sjögren's syndrome patients

References

• Martens PB, Pillemer SR, Jacobsson LT, et al. Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976-1992. J Rheumatol 1999;26:1296-300
   PubMed Web of Science ®Google Scholar
• Pertovaara M, Pukkala E, Laippala P, et al. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467-72
   PubMed Web of Science ®Google Scholar
• Kruize AA, Hené RJ, van der Heide A, et al. Long-term follow-up of patients with Sjögren's syndrome. Arthritis Rheum 1996;39:297-303
   PubMed Web of Science ®Google Scholar
• Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of primary Sjögren's syndrome in north-west Greece. 1982-2003. Rheumatology (Oxford) 2006;45:187-91
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Ramos-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjögren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007;46:1359-62
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Yagüe J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2005;44:89-94
   PubMed Web of Science ®Google Scholar
• Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29:296-304
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7
   PubMed Web of Science ®Google Scholar
• Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Inter Med 1978;89:888-92
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999;42:1765-72
   PubMed Web of Science ®Google Scholar
• Anderson LG, Talal N. The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol 1972;10:199-221
   PubMed Web of Science ®Google Scholar
• Anaya JM, McGuff HS, Banks PM, Talal N. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. Semin Arthritis Rheum 1996;25:337-46
   PubMed Web of Science ®Google Scholar
• Valesini G, Priori R, Bavoillot D, et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome. J Rheumatol 1997;24:2376-80
   PubMed Web of Science ®Google Scholar
• Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjögren's syndrome A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803
   PubMed Web of Science ®Google Scholar
• Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, et al. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 2011;41:415-23
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44
   PubMed Web of Science ®Google Scholar
• Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51-60
   PubMed Web of Science ®Google Scholar
• Kauppi M, Pukkala E, Isomäki H. Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997;8:201-2044
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558.
   PubMed Web of Science ®Google Scholar
• Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87
   PubMed Web of Science ®Google Scholar
• Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites and are not associated with viruses. Blood 1997;90:766-75
   PubMed Web of Science ®Google Scholar
• Mariette X. Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma 1999;33(1-2)):93-9
   PubMed Web of Science ®Google Scholar
• Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009;88:284-93
   PubMed Web of Science ®Google Scholar
• Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009;125:398-405
   PubMed Web of Science ®Google Scholar
• Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-38
   PubMed Web of Science ®Google Scholar
• Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjögren syndrome or hepatitis C virus infection. Br J Haematol 2004;126:43-9
   PubMed Web of Science ®Google Scholar
• Inagaki H, Chan JK, Ng JW, et al. Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features. Am J Pathol 2002;160:1435-43
   PubMed Web of Science ®Google Scholar
• Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: a retrospective clinical study. J Rheumatol 2011;38:2198-208
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Manoussakis MN, Costello R, et al. Cryoglobulinemia in autoimmune rheumatic diseases: evidence of circulating monoclonal cryoglobulins in patients with primary Sjögren's syndrome. Arthritis Rheum 1986;29:1098-104
   PubMed Web of Science ®Google Scholar
• Moutsopoulos HM, Tzioufas AG, Bai MK, et al. Association of serum IgM kappa monoclonicity in patients with Sjögren's syndrome with an increased proportion of kappa positive plasma cells infiltrating the labial minor salivary glands. Ann Rheum Dis 1990;49:929-31
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996;39:767-72
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Salvin S, et al. Cryoglobulinaemia related to Sjögren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. Rheumatology (Oxford) 2012;51:627-33
   PubMed Web of Science ®Google Scholar
• Bassig BA, Zheng T, Zhang Y, et al. Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 2012;53:145-51
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013;8(5):e59868
   PubMed Web of Science ®Google Scholar
• Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjögren's syndrome in a Chinese cohort. Rheumatology (Oxford) 2010;49:571-7
   PubMed Web of Science ®Google Scholar
• Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 1998;28:80-7
   PubMed Web of Science ®Google Scholar
• Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011;70:1363-8
   PubMed Web of Science ®Google Scholar
• De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000;43:94-102
   PubMed Web of Science ®Google Scholar
• De Vita S, De Marchi G, Sacco S, et al. Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. Blood Cells Mol Dis 2001;27:757-66
   PubMed Web of Science ®Google Scholar
• Abbondanzo SL. Extranodal marginal-zone B-cell lymphoma of the salivary gland. Ann Diagn Pathol 2001;5:246-54
   PubMedGoogle Scholar
• De Vita S, De Marchi G, Sacco S, et al. Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. Blood Cells Mol Dis 2001;27:757-66
   PubMed Web of Science ®Google Scholar
• Pijpe J, Kalk WW, van der Wal JE, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2007;46:335-41
   PubMed Web of Science ®Google Scholar
• Marx RE, Hartman KS, Rethman KV. A prospective study comparing incisional labial to incisional parotid biopsies in the detection and confirmation of sarcoidosis, Sjögren's disease, sialosis and lymphoma. J Rheumatol 1988;15:621-9
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Soria N, Muñoz S, et al. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome. Semin Arthritis Rheum 2009;38:389-95
   PubMed Web of Science ®Google Scholar
• Cesana C, Barbarano L, Miqueleiz S, et al. Clinical characteristics and outcome of immunoglobulin M-related disorders. Clin Lymphoma 2005;5:261-4
   PubMedGoogle Scholar
• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-15
   PubMed Web of Science ®Google Scholar
• Kirtava Z, Blomberg J, Bredberg A, et al. CD4+ T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1995;13:609-16
   PubMed Web of Science ®Google Scholar
• Henriksson G, Manthorpe R, Bredberg A, Antibodies to CD4 in primary Sjögren's syndrome. Rheumatology (Oxford) 2000;39:142-7
   PubMed Web of Science ®Google Scholar
• Mandl T, Bredberg A, Jacobsson LT, et al. CD4+ T-lymphocytopenia--a frequent finding in anti-SSA antibody seropositive patients with primary Sjögren's syndrome. J Rheumatol 2004;31:726-8
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Trejo O, García-Carrasco M, et al. Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol 2004;31:495-9
   PubMed Web of Science ®Google Scholar
• Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002;46:2160-71
   PubMed Web of Science ®Google Scholar
• Spachidou MP, Bourazopoulou E, Maratheftis CI, et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome. Clin Exp Immunol 2007;147:497-503
   PubMed Web of Science ®Google Scholar
• Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjögren's syndrome. Arthritis Rheum 2004;50:2897-902
   PubMedGoogle Scholar
• Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998;91:1864-72
   PubMed Web of Science ®Google Scholar
• Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H)genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000;95:3878-84
   PubMed Web of Science ®Google Scholar
• Martin T, Weber JC, Levallois H, et al. Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 2000;43:908-16
   PubMedGoogle Scholar
• Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005;201:1229-41
   PubMed Web of Science ®Google Scholar
• Bahler DW, Miklos JA, Swerdlow SH. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 1997;89:3335-44
   PubMed Web of Science ®Google Scholar
• Jonsson MV, Skarstein K, Jonsson R, Brun JG. Serological implications of germinal center-like structures in primary Sjögren's syndrome. J Rheumatol 2007;34:2044-9
   PubMed Web of Science ®Google Scholar
• Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum 2003;48:3187-201
   PubMed Web of Science ®Google Scholar
• Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjögren's syndrome. Arthritis Rheum 2010;62:2605-10
   PubMed Web of Science ®Google Scholar
• Le Pottier L, Devauchelle V, Fautrel A, et al. Ectopic germinal centers are rare in Sjögren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009;182:3540-7
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Barone F, Humby F, et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren's syndrome. J Immunol 2007;179:4929-38
   PubMed Web of Science ®Google Scholar
• Mackay F, Groom JR, Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol 2007;19:406-13
   PubMed Web of Science ®Google Scholar
• Hansen A, Lipsky PE, Dörner T. B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007;9:218
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH, et al. Association of. BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710
   PubMed Web of Science ®Google Scholar
• Daridon C, Pers JO, Devauchelle V, et al.Identification of transitional type II. B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2006;54:2280-8
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther 2006;8:R51
   PubMed Web of Science ®Google Scholar
• Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003;62:168-71
   PubMed Web of Science ®Google Scholar
• Jonsson MV, Szodoray P, Jellestad S, et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005;25:189-201
   PubMed Web of Science ®Google Scholar
• Manoussakis MN, Boiu S, Korkolopoulou P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007;56:3977-88
   PubMed Web of Science ®Google Scholar
• Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF. APRIL and human B cell disorders. Semin Immunol 2006;18:305-17
   PubMed Web of Science ®Google Scholar
• Bossen C, Schneider P. BAFF. APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-75
   PubMed Web of Science ®Google Scholar
• He B, Chadburn A, Jou E, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-79
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013;52:276-81
   PubMed Web of Science ®Google Scholar
• Nezos A, Papageorgiou A, Fragoulis G, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjögren's syndrome. J Autoimmun 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation. Arthritis Rheum 2013;65:1085-96
   PubMed Web of Science ®Google Scholar
• Lisovsky M, Braun SE, Ge Y, et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996;10:1012-18
   PubMed Web of Science ®Google Scholar
• Antonysamy MA, Thomson AW. Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 2000;12:87-100
   PubMed Web of Science ®Google Scholar
• Tobón GJ, Renaudineau Y, Hillion S, et al. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 2010;62:3447-56
   PubMed Web of Science ®Google Scholar
• Tobón GJ, Saraux A, Gottenberg JE, et al. The FMS-like tyrosine kinase 3-ligand may be biological marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 2013;65:3218-27
   PubMed Web of Science ®Google Scholar